TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $5.51 billion. The enterprise value is $5.75 billion.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 141.72 million shares outstanding. The number of shares has decreased by -2.27% in one year.
| Current Share Class | 141.72M |
| Shares Outstanding | 141.72M |
| Shares Change (YoY) | -2.27% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 4.63% |
| Owned by Institutions (%) | 78.37% |
| Float | 135.10M |
Valuation Ratios
The trailing PE ratio is 13.54 and the forward PE ratio is 22.36. TG Therapeutics's PEG ratio is 1.48.
| PE Ratio | 13.54 |
| Forward PE | 22.36 |
| PS Ratio | 7.87 |
| Forward PS | 7.45 |
| PB Ratio | 9.45 |
| P/TBV Ratio | 9.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.48 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 12.44 |
| EV / Sales | 8.21 |
| EV / EBITDA | 38.43 |
| EV / EBIT | 38.45 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.81, with a Debt / Equity ratio of 1.29.
| Current Ratio | 5.81 |
| Quick Ratio | 4.84 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 4.97 |
| Debt / FCF | n/a |
| Interest Coverage | 5.41 |
Financial Efficiency
Return on equity (ROE) is 112.60% and return on invested capital (ROIC) is 18.89%.
| Return on Equity (ROE) | 112.60% |
| Return on Assets (ROA) | 8.55% |
| Return on Invested Capital (ROIC) | 18.89% |
| Return on Capital Employed (ROCE) | 11.14% |
| Weighted Average Cost of Capital (WACC) | 12.22% |
| Revenue Per Employee | $1.76M |
| Profits Per Employee | $1.16M |
| Employee Count | 399 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | -339.61M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.66% in the last 52 weeks. The beta is 1.68, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | +13.66% |
| 50-Day Moving Average | 35.41 |
| 200-Day Moving Average | 32.26 |
| Relative Strength Index (RSI) | 53.26 |
| Average Volume (20 Days) | 2,234,883 |
Short Selling Information
The latest short interest is 27.03 million, so 19.07% of the outstanding shares have been sold short.
| Short Interest | 27.03M |
| Short Previous Month | 28.73M |
| Short % of Shares Out | 19.07% |
| Short % of Float | 20.00% |
| Short Ratio (days to cover) | 14.90 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $700.35 million and earned $461.90 million in profits. Earnings per share was $2.87.
| Revenue | 700.35M |
| Gross Profit | 581.67M |
| Operating Income | 149.50M |
| Pretax Income | 122.29M |
| Net Income | 461.90M |
| EBITDA | 149.58M |
| EBIT | 149.50M |
| Earnings Per Share (EPS) | $2.87 |
Full Income StatementBalance Sheet
The company has $514.43 million in cash and $753.56 million in debt, with a net cash position of -$239.13 million or -$1.69 per share.
| Cash & Cash Equivalents | 514.43M |
| Total Debt | 753.56M |
| Net Cash | -239.13M |
| Net Cash Per Share | -$1.69 |
| Equity (Book Value) | 583.13M |
| Book Value Per Share | 4.11 |
| Working Capital | 899.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.95 million and capital expenditures -$240,000, giving a free cash flow of -$14.19 million.
| Operating Cash Flow | -13.95M |
| Capital Expenditures | -240,000 |
| Depreciation & Amortization | 83,000 |
| Net Borrowing | 492.66M |
| Free Cash Flow | -14.19M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is 83.05%, with operating and profit margins of 21.35% and 65.95%.
| Gross Margin | 83.05% |
| Operating Margin | 21.35% |
| Pretax Margin | 17.46% |
| Profit Margin | 65.95% |
| EBITDA Margin | 21.36% |
| EBIT Margin | 21.35% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.27% |
| Shareholder Yield | 2.27% |
| Earnings Yield | 8.38% |
| FCF Yield | -0.26% |
Analyst Forecast
The average price target for TG Therapeutics is $48.00, which is 23.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $48.00 |
| Price Target Difference | 23.49% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 20.01% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
TG Therapeutics has an Altman Z-Score of 3.61 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.61 |
| Piotroski F-Score | 3 |
